Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma
Creators
- 1. French Military Health Service Academy, Ecole du Val-de-Grâce, Paris (France)
- 2. Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge (France)
- 3. Brachytherapy Unit, Department of Radiotherapy, Gustave Roussy, Villejuif (France)
- 4. Department of Pediatric Surgery, Bicêtre Hospital, Hôpitaux Universitaires Paris Sud, Assistance Publique des Hôpitaux de Paris, Le Kremlin-Bicêtre (France)
- 5. Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif (France)
- 6. Faculté de Médecine Paris Sud, Université Paris Sud, Université Paris Saclay, Paris (France)
Description
Purpose: To report the results of a conservative strategy based on partial surgery combined with brachytherapy in a prospective cohort of children with bladder–prostate rhabdomyosarcoma (BP RMS). Methods and Materials: We prospectively documented the outcome of children treated in our department between 1991 and 2015 for BP RMS and undergoing a multimodal approach combining conservative surgery (partial cystectomy and/or partial prostatectomy) and perioperative interstitial low-dose-rate or pulse-dose-rate brachytherapy. Before brachytherapy, children had received chemotherapy with modalities depending on their risk group of treatment. Results: A total of 100 patients were identified, with a median age of 28 months (range, 5.6 months-14 years). According to the Intergroup Rhabdomyosarcoma Study (IRS) group, 84 were IRS-III, and 12 were IRS-IV tumors. Four patients were treated at relapse. The median number of chemotherapy cycles before local therapy was 6 (range, 4-13). After surgery, 63 patients had a macroscopic tumor residuum. Five patients underwent a brachytherapy boost before pelvic external beam radiation therapy because of nodal involvement, and 95 had exclusive brachytherapy. Median follow-up was 64 months (range, 6 months-24.5 years). Five-year disease-free and overall survival rates were 84% (95% confidence interval 80%-88%) and 91% (95% confidence interval 87%-95%), respectively. At last follow-up most survivors presented with only mild to moderate genitourinary sequelae and a normal diurnal urinary continence. Five patients required a secondary total cystectomy: 3 for a nonfunctional bladder and 2 for relapse. Conclusion: Brachytherapy is effective as part of a conservative strategy for BP RMS, with a relatively low delayed toxicity as compared with previously published studies using external beam radiation therapy. Longer follow-up is required to ensure that the functional results are maintained over time.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2017.02.026Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2017.02.026;
- PII
- S0360-3016(17)30404-2;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 98
- Journal Issue
- 2
- Journal Page Range
- p. 352-359
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 48098590
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BLADDER; BRACHYTHERAPY; CHEMOTHERAPY; CHILDREN; CONNECTIVE TISSUE; EXTERNAL BEAM RADIATION THERAPY; PATIENTS; RADIATION HAZARDS; RHABDOMYOSARCOMAS; SURGERY
- Descriptors DEC
- AGE GROUPS; ANIMAL TISSUES; ANIMALS; BODY; DISEASES; HAZARDS; HEALTH HAZARDS; MAMMALS; MAN; MEDICINE; MYOSARCOMAS; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; PRIMATES; RADIOLOGY; RADIOTHERAPY; SARCOMAS; THERAPY; URINARY TRACT; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2017 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.